APGE (Apogee Therapeutics) Accumulated Depreciation: $-2.38 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APGE Apogee Therapeutics Inc APGE
22 GF Score
Price $134.81
! 3 Warning Signs
View Full Analysis

What is Apogee Therapeutics Accumulated Depreciation?

Apogee Therapeutics APGE +0.04% 22 Accumulated Depreciation is $-2.38 Mil as of Jun. 2026. GuruFocus rates APGE with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Apogee Therapeutics's quarterly accumulated depreciation increased from Dec. 2025 ($-1.61 Mil) to Mar. 2026 ($-2.02 Mil) and increased from Mar. 2026 ($-2.02 Mil) to Jun. 2026 ($-2.38 Mil).

Apogee Therapeutics's annual accumulated depreciation increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.19 Mil) and increased from Dec. 2024 ($-0.19 Mil) to Dec. 2025 ($-1.61 Mil).

Apogee Therapeutics Accumulated Depreciation Related Terms

Apogee Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Apogee Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apogee Therapeutics Accumulated Depreciation Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
0.00 0.00 -0.19 -1.61

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.80 -1.20 -1.61 -2.02 -2.38
APGE
22GF Score
Apogee Therapeutics Inc APGE
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apogee Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-2.38 Mil mean?
Apogee Therapeutics (APGE) has a Accumulated Depreciation of $-2.38 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Apogee Therapeutics and its competitors.
Is Apogee Therapeutics' Accumulated Depreciation too high?
Apogee Therapeutics' current Accumulated Depreciation is $-2.38 Mil. Overall, Apogee Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' Accumulated Depreciation compare to CORT and KRYS?
Apogee Therapeutics' Accumulated Depreciation of $-2.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Apogee Therapeutics and its competitors. Apogee Therapeutics's current Accumulated Depreciation is $-2.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current Accumulated Depreciation of $-2.38 Mil. The current Accumulated Depreciation is $-2.38 Mil. Apogee Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current Accumulated Depreciation is $-2.38 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apogee Therapeutics Business Description

Address 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
22GF Score

Get the complete analysis for APGE

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$134.81
Price